Q-omics provides the consensus-scored SYDE2 profile across patient tissues and cancer cell-line models. SYDE2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SYDE2 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, SYDE2 RNA expression shows 19,461 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where SYDE2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYDE2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYDE2 survival associations across molecular data types. SYDE2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYDE2 RNA expression–survival associations across cancer types. High SYDE2 expression shows unfavorable associations in UCEC and ACC, but favorable associations in KIRC, UCS, BRCA and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SYDE2 RNA expression.
This table summarizes SYDE2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SYDE2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYDE2 shows lower tumor expression in KICH, THCA, KIRP, KIRC, LUSC and LUAD. The KICH box plot shows higher SYDE2 RNA expression in normal versus tumor tissue (log2 FC = −1.393, t-test p < 0.001).
This table shows molecular features associated with SYDE2 in patient tissues and cancer cell lines. In patient samples, SYDE2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SYDE2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
